Pharmacological management of heart failure: a patient-centred approach.

IF 2.5 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-11-11 DOI:10.1080/14656566.2024.2418414
Guglielmo Fibbi, Ryosuke Sato, Mirela Vatic, Frederik Pascal Genreith, Stephan von Haehling
{"title":"Pharmacological management of heart failure: a patient-centred approach.","authors":"Guglielmo Fibbi, Ryosuke Sato, Mirela Vatic, Frederik Pascal Genreith, Stephan von Haehling","doi":"10.1080/14656566.2024.2418414","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Heart failure (HF) is a global health challenge that requires a multidisciplinary approach. Despite recent advances in pharmacological and interventional therapy, morbidity and mortality in these patients remain high. For this reason, and because of its interplay with other cardiovascular and non-cardiovascular diseases, HF represents a major area of research, with new trials being published every year and international guidelines constantly updated.</p><p><strong>Areas covered: </strong>The authors review the current status and possible future developments in HF pharmacotherapy.</p><p><strong>Expert opinion: </strong>The treatment of HF has made significant advances in recent years, and the current recommendations are based on large outcome trials. This has led to significant reductions in both mortality and morbidity, but the death rate remains unacceptably high. In this context, a patient-centered approach that considers comorbidities and specific clinical scenarios when dosing HF medication is essential. Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2151-2165"},"PeriodicalIF":2.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/14656566.2024.2418414","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/11 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Heart failure (HF) is a global health challenge that requires a multidisciplinary approach. Despite recent advances in pharmacological and interventional therapy, morbidity and mortality in these patients remain high. For this reason, and because of its interplay with other cardiovascular and non-cardiovascular diseases, HF represents a major area of research, with new trials being published every year and international guidelines constantly updated.

Areas covered: The authors review the current status and possible future developments in HF pharmacotherapy.

Expert opinion: The treatment of HF has made significant advances in recent years, and the current recommendations are based on large outcome trials. This has led to significant reductions in both mortality and morbidity, but the death rate remains unacceptably high. In this context, a patient-centered approach that considers comorbidities and specific clinical scenarios when dosing HF medication is essential. Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials.

心力衰竭的药物治疗:以患者为中心的方法。
导言心力衰竭(HF)是一项全球性的健康挑战,需要采用多学科方法进行治疗。尽管最近在药物治疗和介入治疗方面取得了进展,但这些患者的发病率和死亡率仍然居高不下。由于这一原因,并由于其与其他心血管和非心血管疾病的相互作用,心力衰竭是一个重要的研究领域,每年都有新的试验发表,国际指南也在不断更新:作者回顾了心房颤动药物治疗的现状和未来可能的发展:专家观点:近年来,心房颤动的治疗取得了重大进展,目前的建议均以大型结果试验为基础。这使得死亡率和发病率均大幅下降,但死亡率仍然高得令人无法接受。在这种情况下,必须采取以患者为中心的方法,在使用高血压药物时考虑到合并症和特定的临床情况。对于心房颤动患者来说,预防因心脏失代偿而入院至关重要,同样重要的是使患者能够进行日常生活活动,而这一终点直到最近才被纳入主要的心房颤动试验中。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信